Positive interim data from RCT of proxalutamide in hospitalised patients with Covid-19

Analysis found proxalutamide (300mg daily for 14 days) was associated with a larger reduction in the Covid-19 Ordinal scale than placebo on day 14 (4.01 versus 0.25, respectively), with a lower mortality risk at day 14 (3.7% v 46.7%) & reduced median hospital stay (5 v 14 days)

Source:

Biospace Inc.